secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERU INC. (VERU)
CIK:        0000863894
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001193125-23-208059
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veru Q3 net income $6.3M on ENTADFI gain; pipeline updates for enobosarm, sabizabulin
--------------------------------------------------------------------------------

- Net income $6.3M ($0.07/diluted share) vs net loss $22.2M ($0.28) in Q3 2022; revenue $3.3M down from $9.6M.
- Cash burn reduced to $7.3M in Q3, down $16.1M from prior quarter; cash $16.2M at June 30, 2023.
- Sold ENTADFI for $20M in April 2023; potential $80M in sales milestones. Gain of $17.5M recognized.
- FDA agrees on Phase 3 ENABLAR-2 design; ORR endpoint in Stage 1 may support accelerated approval for enobosarm in metastatic breast cancer.
- Plans to expand sabizabulin Phase 3 confirmatory study to all viral lung infections; FDA meeting scheduled for September 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/863894/000119312523208059/0001193125-23-208059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/863894/000119312523208059/d463183d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-208059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer